SciSparc Gets Renewal From Israeli Medical Cannabis Agency for Autism Spectrum Disorder Trial

MT Newswires Live2024-12-31

SciSparc (SPRC) said Tuesday that the Israeli Medical Cannabis Agency at the Israeli Ministry of Health renewed an approval for the clinical trial of SCI-210 in children with autism spectrum disorder, or ASD.

The 30-day approval is expected to be extended upon final Israeli police approval, expected within the same timeframe, SciSparc said.

The SCI-210 clinical trial is a double-blind, randomized, placebo-controlled study at Soroka University Medical Center in Israel, involving 60 children aged 5 to18 with ASD, the pharmaceutical company said.

The 20-week trial will evaluate the efficacy and safety of SCI-210, which is a combination of a proprietary cannabidiol, or CBD, and CannAmide, against standard CBD therapy. The trial will focus on symptom management and therapeutic outcomes, SciSparc said, adding that it aims to launch SCI-210 in Israel first, with plans for international expansion pending regulatory approvals.

Price: 0.44, Change: -0.02, Percent Change: -4.98

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2495615040?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-31 22:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2495615040","market":"hk","top_or_hot":-1,"title":"SciSparc Gets Renewal From Israeli Medical Cannabis Agency for Autism Spectrum Disorder Trial","media":"MT Newswires Live","content":"<html><body><p> SciSparc (SPRC) said Tuesday that the Israeli Medical Cannabis Agency at the Israeli Ministry of Health renewed an approval for the clinical trial of SCI-210 in children with autism spectrum disorder, or ASD.</p><p>The 30-day approval is expected to be extended upon final Israeli police approval, expected within the same timeframe, SciSparc said.</p><p>The SCI-210 clinical trial is a double-blind, randomized, placebo-controlled study at Soroka University Medical Center in Israel, involving 60 children aged 5 to18 with ASD, the pharmaceutical company said.</p><p>The 20-week trial will evaluate the efficacy and safety of SCI-210, which is a combination of a proprietary cannabidiol, or CBD, and CannAmide, against standard CBD therapy. The trial will focus on symptom management and therapeutic outcomes, SciSparc said, adding that it aims to launch SCI-210 in Israel first, with plans for international expansion pending regulatory approvals.</p><p>Price: 0.44, Change: -0.02, Percent Change: -4.98</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SciSparc Gets Renewal From Israeli Medical Cannabis Agency for Autism Spectrum Disorder Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSciSparc Gets Renewal From Israeli Medical Cannabis Agency for Autism Spectrum Disorder Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-31 22:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SciSparc (SPRC) said Tuesday that the Israeli Medical Cannabis Agency at the Israeli Ministry of Health renewed an approval for the clinical trial of SCI-210 in children with autism spectrum disorder,...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SPRC","symbol_name":"SciSparc Ltd.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2495615040","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2495615040","pubTimestamp":1735656870,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"SciSparc  said Tuesday that the Israeli Medical Cannabis Agency at the Israeli Ministry of Health renewed an approval for the clinical trial of SCI-210 in children with autism spectrum disorder, or ASD.The 30-day approval is expected to be extended upon final Israeli police approval, expected within the same timeframe, SciSparc said.The SCI-210 clinical trial is a double-blind, randomized, placebo-controlled study at Soroka University Medical Center in Israel, involving 60 children aged 5 to18 with ASD, the pharmaceutical company said.The 20-week trial will evaluate the efficacy and safety of SCI-210, which is a combination of a proprietary cannabidiol, or CBD, and CannAmide, against standard CBD therapy. The trial will focus on symptom management and therapeutic outcomes, SciSparc said, adding that it aims to launch SCI-210 in Israel first, with plans for international expansion pending regulatory approvals.Price: 0.44, Change: -0.02, Percent Change: -4.98","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SPRC":"SciSparc Ltd.","BK4557":"大麻股","ACB":"奥罗拉大麻公司","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","BK4018":"居家用品","BK4007":"制药","BK4139":"生物科技","SPB":"Spectrum Brands Holdings"},"translate_title":"SciSparc获得以色列医用大麻机构的自闭症谱系障碍试验续约","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPB":1,"SPRC":0.9,"ACB":0.73},"content_text":"SciSparc (SPRC) said Tuesday that the Israeli Medical Cannabis Agency at the Israeli Ministry of Health renewed an approval for the clinical trial of SCI-210 in children with autism spectrum disorder, or ASD.The 30-day approval is expected to be extended upon final Israeli police approval, expected within the same timeframe, SciSparc said.The SCI-210 clinical trial is a double-blind, randomized, placebo-controlled study at Soroka University Medical Center in Israel, involving 60 children aged 5 to18 with ASD, the pharmaceutical company said.The 20-week trial will evaluate the efficacy and safety of SCI-210, which is a combination of a proprietary cannabidiol, or CBD, and CannAmide, against standard CBD therapy. The trial will focus on symptom management and therapeutic outcomes, SciSparc said, adding that it aims to launch SCI-210 in Israel first, with plans for international expansion pending regulatory approvals.Price: 0.44, Change: -0.02, Percent Change: -4.98","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2495615040"}